ABSTRACT A detailed pharmacokinetic study of cefuroxime has been carried out. Levels of cefuroxime were determined in the blood, sputum, saliva, and urine of 23 patients receiving parenteral cefuroxime eight hourly for chest infections. Profiles were obtained after the first dose and on the final (fifth) day of treatment. Antibiotic levels in the sputum reached 0-8 mg/l within one hour of the first injection, and were maintained close to this value for six hours. There was a build-up by the fifth day, mean cefuroxime concentrations at this time reaching 1 8 mg/l. This concentration was maintained for a prolonged period. Salivary concentrations were detectable but low (maximum mean value was 0-6 mg/l). Concentrations of antibiotic were significantly higher in the serum than those observed after the same doses in volunteers. In the patients there was no build-up in serum levels between the first and fifth days. The data obtained explain the clinical efficacy of cefuroxime in the treatment of lower respiratory infections, and suggest that a 12-hour schedule may be feasible.
Cefuroxime is a new cephalosporin, very stable to f-lactamases and highly active against many pathogenic bacteria.' Preliminary clinical studies have been encouraging,2 and we have found cefuroxime to be very effective in the treatment of infections of the lower respiratory tract.3 During the course of the latter trial, we measured cefuroxime concentrations at numerous intervals in the sputum, saliva, and blood of the patients. Our results, reported here, help to explain why cefuroxime is effective in this type of patient.
Patients and methods
Twenty-three patients suffering from lower respiratory tract infections (13 bronchopneumonia, 10 acute exacerbation of chronic bronchitis) were treated with parenteral cefuroxime (Zinacef), thrice daily for five days. The pharmacokinetic behaviour of the antibiotic was studied in these patients during their treatment.
PHARMACOKINETIC PROFILES
The full profile involved taking blood at the following times after injection of the antibiotic: 0-25, 0.5, 0-75, 1, 1-5, 2, 3, 4, 5, 6, 7, and 8 hours.
Address for reprint requests: Dr CWH Havard, Royal Northern Hospital, Holloway Road, London N7 6LD. 
Discussion
It is interesting to compare our results concerning serum levels of cefuroxime with those obtained in volunteers. After the 750 mg intramuscular dose, we observed higher and more prolonged levels, with peak concentrations being reached slightly later, than did Foord5 and Nakagawa." Further, our figures are somewhat higher than those observed by Daikos et al,7 also in patients. We did not find increased peak concentrations after the 1 g intramuscular dose, but rather a plateau was observed in the concentration/time profile; Nakagawa" obtained very bimilar findings in volunteers. Foord5 had earlier discovered that there was no proportionality for cefuroxime between the dose administered and the peak serum level, such as exists for other f8-lactam antibiotics like ampicillin.8 There was no evidence of accumulation of cefuroxime on the currently adopted eight-hour dosage schedule. An interesting finding here was that cefuroxime disappeared from the serum more slowly than previous experience in volunteers would suggest.5 6 This is presumably because our patients, as a group, were elderly, and consequently would be expected to have some degree of renal function impairment. The rate of cefuroxime clearance from the body is known to be affected markedly by changes in renal function.9 This notion is supported by our finding that only just over half the given dose of antibiotic was excreted within eight hours, in contrast to the virtually complete recovery in healthy volunteers.5 6 There is little accurate information available on sputum levels of antibiotics. In our experience the ideal method for obtaining sputum for such a study is cricoid puncture but this has not yet been used with cefuroxime. Bergogne-Berezon et al10 showed, in patients undergoing tracheostomy or fibreoptic bronchoscopy, that cefuroxime attains effective levels in the sputum earlier than other f3-lactam antibiotics. If expectorated sputum is assayed, as was done here, a prerequisite for accurate interpretation of results is knowledge of saliva levels. We have shown that the latter are not only low, but also fall away relatively rapidly, in contrast to the levels in the sputum, which are well maintained during the eight-hour interval between doses. The penetration of cefuroxime into sputum is clearly not related to the degree of purulence-levels were twice as high after five days of treatment, at which time sputum purulence had decreased markedly. 3 May and Ingold" suggested that "the drug concentration in sputum is important in relation to the sterilisation of reservoirs of organisms from which relapse after treatment may stem, and that the highest attainable sputum concentration of ampicillin and amoxycillin was insufficient to inhibit all strains of H influenzae, while the concentrations observed in many patients were too low to inhibit any strains." The second part of this statement certainly does not apply to cefuroxime: the mean sputum level achieved one hour after the first 750 mg intramuscular dose is 1 mg/l, which will be inhibitory for H influenzae (MIC 0-5 mg/l), S pneumoniae (MIC 0-25 mg/l), and penicillinase-producing staphylococci (MIC 1 mg/l).
Our pharmacokinetic findings help to explain why cefuroxime is so effective in the treatment of lower respiratory tract infections. Its rapid penetration into, and slow excretion from, the sputum is clearly a very useful property in this respect. The persistence of cefuroxime in the sputum suggests that it may be possible to give the drug on a twice-daily schedule. 
